SCHEMBL18158963

SCHEMBL18158963

Cc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)C(O)[C@@H]2O)c(=O)[nH]1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 3/20 0.68
IMPDH2 P12268 6/20 0.68
IMPDH1 P20839 2/20 0.68
TGM2 P21980 1/20 0.66
P2RY1 P47900 4/20 0.65
ENPP1 P22413 2/20 0.65
P2RX1 P51575 1/20 0.65
P2RY6 Q15077 1/20 0.65
P2RY11 Q96G91 1/20 0.65
P2RX4 Q99571 1/20 0.65
TAS1R3 Q7RTX0 1/20 0.65
TAS1R1 Q7RTX1 1/20 0.65
RNASEL Q05823 1/20 0.64
P2RY12 Q9H244 1/20 0.64
FUT5 Q11128 1/20 0.63
KRAS P01116 2/20 0.62
P2RX2 Q9UBL9 1/20 0.62
NT5E P21589 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18289612 1.00 P2RX3 (0.68) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL18269536 1.00 P2RX3 (0.68) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL15746475 0.93 IMPDH2 (0.66) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL16805270 0.93 IMPDH2 (0.66) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL15702882 0.93 TGM2 (0.68) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL15746465 0.92 P2RX3 (0.58) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL15746485 0.92 IMPDH2 (0.65) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL16805277 0.92 IMPDH2 (0.65) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL15746483 0.92 P2RX3 (0.66) P2RX3IMPDH2IMPDH1TGM2P2RY1
SCHEMBL16805280 0.92 P2RX3 (0.66) P2RX3IMPDH2IMPDH1TGM2P2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2017-05-18 US disclosed
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 US disclosed
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 US disclosed
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-01 US disclosed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885IMPDH2 451/4885IMPDH1 496/4885
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885IMPDH2 451/4885IMPDH1 496/4885
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885IMPDH2 451/4885IMPDH1 496/4885
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 P2RX3 2081/4885IMPDH2 462/4885IMPDH1 586/4885
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885IMPDH2 451/4885IMPDH1 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.